OncLive SOSS

Authors

Vincent T. Ho, MD, Dana-Farber Cancer Institute

Vincent Vandecaveye, MD, PhD

Latest:

Dr. Vandecaveye on Diffusion MRI for Tumor Differentiation

Vincent Vandecaveye, MD, PhD, University Hospitals Leuven, discusses developments of magnetic resonance imaging, specifically diffusion MRI, as a method to differentiate tumors and disease stages.

Vincent Y. Ng, MD

Latest:

Dr. Ng on Immunotherapy in Micrometastatic High-Risk Soft Tissue Sarcoma

Vincent Y. Ng, MD, discusses immunotherapy in micrometastatic high-risk soft tissue sarcoma.

Vinod A. Pullarkat, MD

Latest:

Dr. Pullarkat on Treatment Strategies in Transplant Ineligible ALL

Vinod A. Pullarkat, MD, clinical professor of Hematology & Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses treatment strategies in transplant ineligible acute lymphoblastic leukemia (ALL).

Vinod Pullarkat, MD, City of Hope Medical Center

Latest:

Treatment Approaches for TP53-Mutated AML

Key opinion leaders in hematology oncology share insights into the challenges associated with treating patients with TP53-mutated AML and highlight the recent FDA breakthrough designation of eprenetapopt.

Viola Poeschel, MD

Latest:

Dr. Poeschel on 6 Versus 4 Cycles of R-CHOP in Frontline DLBCL

Viola Poeschel, MD, department of hematology, oncology and rheumatology, Saarland University Medical School, Germany, discusses outcomes of patients with diffuse large B-cell lymphoma (DLBCL) who were treated with 4 cycles of R-CHOP during the 2018 ASH Annual Meeting.

Viola W. Zhu, MD, PhD

Latest:

Dr. Zhu on TMB in Lung Cancer

Viola W. Zhu, MD, PhD, medical oncologist/hematologist, University of California, Irvine, discusses tumor mutational burden (TMB) in lung cancer.

Vip Viprakasit, MD, DPhil

Latest:

Dr. Viprakasit on the Results of the BELIEVE Trial With Luspatercept in Beta-Thalassemia

Vip Viprakasit, MD, DPhil, professor of Pediatrics, and director, Thalassemia Research, Siriraj-Thalassemia Center, Siriaj Hospital, discusses the results of the multicenter BELIEVE trial with luspatercept (Reblozyl) in adult patients with β-thalassemia.

Viraj Master, MD, PhD

Latest:

Novel VIL Approach Reduces Complications From Regional Lymphadenectomy in Melanoma

Surgical intervention is a Machiavellian endeavor: the ends justify the means. This obligates the clinician to minimize the risk of a procedure to justify the gains obtained from an intervention.

Virgina Powers, PhD

Latest:

Sitravatinib/Tislelizumab Combo Active in Advanced Ovarian Cancer

The novel combination of sitravatinib and tislelizumab showed encouraging antitumor activity and a manageable safety profile in patients with advanced ovarian cancer.

Virginia Kaklamani, MD, University of Texas Health Science Center

Latest:

Addressing Resistance to HER2-Targeted Therapy in Metastatic Breast Cancer

Comprehensive insight on acquired resistance to HER2-targeted therapy in metastatic breast cancer, and how treatments can be selected and sequenced thereafter.

Virginia Powers

Latest:

Frontline Atezolizumab Combo Emerges as Potential New Standard in NSCLC

The frontline regimen of atezolizumab (Tecentriq), bevacizumab (Avastin), carboplatin, and paclitaxel has emerged as a potential new standard of care for the treatment of patients with metastatic nonsquamous NSCLC.

Virginia Powers, PhD

Latest:

Transplantation Using Haploidentical Donors Outperforms Matched Sibling Donors in MRD+ ALL

Haploidentical donor transplantation led to stronger anti-leukemia activity compared with matched sibling donor transplantation in transplant-eligible patients with minimal residual disease–positive acute lymphoblastic leukemia.

Virginia Vachon

Latest:

Expert Discusses Neoadjuvant Treatment Potential in Advanced RCC

Neoadjuvant therapy is evolving as a treatment approach for patients with advanced renal cell carcinoma.

Vishal Ranpura, MD

Latest:

Selecting Your Career Path

Medical education and training is very intense, long, and expensive. When nearing the end of training, it is time to select a career path.

Vitaly Gordin, MD, Penn State Hershey

Vitaly Margulis, MD, UT Southwestern Medical Center

Latest:

Dr Margulis on Key Considerations When Navigating Frontline Combination Regimens in RCC

Vitaly Margulis, MD, discusses key disease characteristics and patient factors to consider when selecting between IO/IO vs IO/TKI treatment combinations for the management of patients with renal cell carcinoma.

Vivek N. Patel, MD

Latest:

Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.

Vivek S. Kavadi, MD

Latest:

Maintaining the Pace of Progress

Over the past 40 years, since the declaration of the War on Cancer in 1971, we have seen tremendous advances in our struggle with this deadly disease.

Vivek Subbiah, MD, MD Anderson Cancer Center

Latest:

Dr. Subbiah on the FDA Approval of Dabrafenib/Trametinib in BRAF V600E–Mutated Solid Tumors

Vivek Subbiah, MD, discusses the FDA approval of dabrafenib plus trametinib for the treatment of patients with BRAF V600E–mutated unresectable or metastatic solid tumors.